Abstract | PURPOSE OF REVIEW: Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal. This article reviews randomized trials and recent studies on chemoradiation for anal cancer. RECENT FINDINGS: SUMMARY: The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial ( Anal Cancer Trial II) may help clarify the role of cisplatin. Studies on tumor biology and patient genetics are warranted to identify patients that are most likely to benefit from newer locoregional and systemic therapies. Intensity modulated radiation therapy appears to be a promising approach for reducing treatment-related toxicity in anal cancer patients. The Radiation Therapy Oncology Group (RTOG) is conducting a phase II trial evaluating the multi-institutional feasibility of intensity modulated radiation therapy for anal cancer.
|
Authors | Prajnan Das, Christopher H Crane, Jaffer A Ajani |
Journal | Current opinion in oncology
(Curr Opin Oncol)
Vol. 19
Issue 4
Pg. 396-400
(Jul 2007)
ISSN: 1040-8746 [Print] United States |
PMID | 17545807
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Radiation-Sensitizing Agents
- Mitomycin
- Cisplatin
- Fluorouracil
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Anus Neoplasms
(drug therapy, radiotherapy)
- Carcinoma, Squamous Cell
(drug therapy, radiotherapy)
- Cisplatin
(therapeutic use)
- Fluorouracil
(therapeutic use)
- Humans
- Mitomycin
(therapeutic use)
- Radiation-Sensitizing Agents
(therapeutic use)
- Radiotherapy, Intensity-Modulated
|